Cardiovascular Toxicities Associated with Cancer Immunotherapies
Daniel Y. Wang, Gosife Donald Okoye, Thomas Neilan et al. · Current Cardiology Reports · 2017
Cited by 157 works. doi:10.1007/s11886-017-0835-0 Open-access PDF
Authors
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Cancer Statistics, 2008
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation